 Three phase three clinical trials were conducted to assess the safety, reactogenicity, immunogenicity, and persistence of immune responses to the combined dipheria, tetanus, pertussis, poliomyelitis, and hemophilus influenza type B vaccine, DT-PAIPV, HIV, in Chinese infants and toddlers. The pilot study demonstrated non-inferiority of three-dose primary vaccination with DT-PAIPV, HIV over separately administered DT-PA, HIV and IPV, while the booster study showed similar antibody concentrations in all groups except for antipolyribosylribotor phosphate and antipolyovirus types 1-3. The three-dose vaccination with DT-PAIPV, HIV had a clinically acceptable safety profile. This article was authored by Yang Ping Li, Rong Cheng Li, Zhong Yi, and others.